In contrast, the BCL2L1 gene shows differential splicing in both AML and CML [99,102], promoting the anti-apoptotic form BCL-XL, thus explaining a survival advantage and TKI resistance [102]. Here, BCL2L1 is linked to acute myeloid leukemia.